An Open Label Trial of Bupropion and Naltrexone for Binge Drinking
Assessing Changes in the Brain Melanocortin System and Sensory Processing in Response to Alcohol to Advance Our Understanding of the Pathophysiology and Psychopharmacology of Binge Drinking
Sponsor: North Carolina Translational and Clinical Sciences Institute
Listed as NCT02842073, this PHASE2 trial focuses on Binge Drinking and remains completed. Sponsored by North Carolina Translational and Clinical Sciences Institute, it has been updated 11 times since 2016, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE2
-
Jul 2018 — Jan 2019 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Completed PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Dec 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
-
Nov 2017 — Dec 2017 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2017 — Nov 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- North Carolina Translational and Clinical Sciences Institute
- University of North Carolina, Chapel Hill
For direct contact, visit the study record on ClinicalTrials.gov .